Literature DB >> 31996354

Is bronchiectasis really a disease?

Michal Shteinberg1,2, Patrick A Flume3, James D Chalmers4.   

Abstract

The definition of a disease requires that distinguishing signs and symptoms are present that are common, and that the constellation of signs and symptoms differentiate the condition from other causes. In bronchiectasis, anatomical changes, airways inflammation and airway infection are the distinguishing features that are common to this disease. However, bronchiectasis is a heterogenous disease: signs and symptoms are shared with other airway diseases, there are multiple aetiologies and certain phenotypes of bronchiectasis have distinct clinical and laboratory features that are not common to all people with bronchiectasis. Furthermore, response to therapeutic interventions in clinical trials is not uniform. The concept of bronchiectasis as a treatable trait has been suggested, but this may be too restrictive in view of the heterogeneity of bronchiectasis. It is our opinion that bronchiectasis should be defined as a disease in its own right, but one that shares several pathophysiological features and "treatable traits" with other airway diseases. These traits define the large heterogeneity in the pathogenesis and clinical features and suggest a more targeted approach to therapy.
Copyright ©ERS 2020.

Entities:  

Year:  2020        PMID: 31996354     DOI: 10.1183/16000617.0051-2019

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  4 in total

1.  Strong and consistent associations of precedent chronic rhinosinusitis with risk of non-cystic fibrosis bronchiectasis.

Authors:  Brian S Schwartz; Saba A Al-Sayouri; Jonathan S Pollak; Annemarie G Hirsch; Robert Kern; Bruce Tan; Atsushi Kato; Robert P Schleimer; Anju T Peters
Journal:  J Allergy Clin Immunol       Date:  2022-03-18       Impact factor: 14.290

2.  Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis.

Authors:  Concetta Lipardi; C Gregory Elliott; Chiara L Sugarmann; Lloyd Haskell; Alex C Spyropoulos; Gary E Raskob; Jianfeng Xu; Wentao Lu; Jessica Marsigliano; Theodore Spiro; Zhong Yuan; Shujian Wu; Elliot S Barnathan
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

3.  Treatable Traits in Chronic Respiratory Disease: A Comprehensive Review.

Authors:  Yong Qin Lee; Asvin Selvakumar; Kay Choong See
Journal:  Cells       Date:  2021-11-22       Impact factor: 6.600

4.  4-week daily airway clearance using oscillating positive-end expiratory pressure versus autogenic drainage in bronchiectasis patients: a randomised controlled trial.

Authors:  Galit Livnat; Naama Yaari; Nili Stein; Lea Bentur; Moneera Hanna; Maya Harel; Yochai Adir; Michal Shteinberg
Journal:  ERJ Open Res       Date:  2021-11-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.